BeOne Medicines AG (HKG:6160)
Hong Kong · Delayed Price · Currency is HKD 194.00
-2.10 (-1.07%)
Jul 31, 2026, 4:08 PM HKT
BeOne Medicines AG Stock Forecast
Stock Price Forecast
According to 16 analysts polled by S&P Global, BeOne Medicines AG stock has a consensus rating of "Strong Buy" and an average price target of $256.62. The average 1-year stock price forecast is 32.28% higher than the current stock price, while the lowest is $212.60 (+9.59%) and the highest is $298.44 (+53.84%).
Price Target: $256.62 (+32.28%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for BeOne Medicines AG stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 14 | 14 | 14 | 13 | 13 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 17 | 17 | 17 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Nomura No rating | Nomura | Buy Maintains $270.74 | Buy | Maintains | $270.74 | +39.56% | Jul 24, 2026 |
Unknown Analyst UBS No rating | UBS | Buy Maintains $273.60 | Buy | Maintains | $273.60 | +41.03% | Jul 23, 2026 |
Unknown Analyst Macquarie No rating | Macquarie | Buy Maintains $257.00 | Buy | Maintains | $257.00 | +32.47% | Jul 13, 2026 |
Unknown Analyst HSBC No rating | HSBC | Buy Maintains $225.60 | Buy | Maintains | $225.60 | +16.29% | Jul 10, 2026 |
Unknown Analyst Huafu Securities No rating | Huafu Securities | Buy Maintains $297.44 | Buy | Maintains | $297.44 | +53.32% | Jul 7, 2026 |
Financial Forecast
Revenue This Year
6.51B
from 5.34B
Increased by 21.81%
Revenue Next Year
7.45B
from 6.51B
Increased by 14.53%
EPS This Year
0.50
from 0.19
Increased by 162.93%
EPS Next Year
0.76
from 0.50
Increased by 52.72%
EPS and Forward PE are based on non-GAAP adjusted numbers.